Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04296266 · ClinicalTrials.gov registry record · Early Phase 1
Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT04296266: Completed Early Phase 1 study, sponsored by Stanford University.
NCT04296266 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04296266, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is determine salivary gland disposition of d-limonene, the primary component in citrus peel and a common dietary supplement. Salivary gland tissue and saliva will be collected to determine concentration of d-limonene and its metabolites in these tissues.
Interventions
- DRUG Alda-341
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-12-21 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04296266
The ClinicalTrials.gov registry entry for NCT04296266 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alda-341 is the first listed.
NCT04296266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04296266 about?
NCT04296266 is a clinical study titled "Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery". The purpose of this study is determine salivary gland disposition of d-limonene, the primary component in citrus peel and a common dietary supplement. Salivary gland tissue and saliva will be collected to determine concentration of d-limonene and its metabolites in these tissues.
What is the current status of trial NCT04296266?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2016-02. Estimated completion is 2017-12-21.
What interventions are being tested in trial NCT04296266?
The interventions under investigation include: Alda-341 (DRUG).
Who is sponsoring clinical trial NCT04296266?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.